{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:10:47Z","timestamp":1791159047351,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.bcmd.2012.09.006","type":"journal-article","created":{"date-parts":[[2012,10,22]],"date-time":"2012-10-22T17:47:50Z","timestamp":1350928070000},"page":"134-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease"],"prefix":"10.1016","volume":"50","author":[{"given":"Ari","family":"Zimran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheona","family":"Altarescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Elstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2012.09.006_bb0005","series-title":"Gaucher Disease","first-page":"13","article-title":"Gaucher disease: molecular biology and genotype\u2013phenotype correlations","author":"Hruska","year":"2007"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0010","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0015","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1111\/j.1742-4658.2006.05410.x","article-title":"Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients","volume":"273","author":"Chang","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0020","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/cbic.200800304","article-title":"Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen\/deuterium exchange mass spectrometry","volume":"9","author":"Tropak","year":"2008","journal-title":"Chembiochem"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cmdc.201000469","article-title":"Second-generation iminoxylitol-based pharmacological chaperones for the treatment of Gaucher disease","volume":"6","author":"Oula\u00efdi","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0030","series-title":"Williams Hematology","first-page":"1065","article-title":"Lipid storage diseases","author":"Zimran","year":"2010"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0035","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme-enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF00441781","article-title":"A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis","volume":"144","author":"Ratjen","year":"1985","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1447-0756.2000.tb01327.x","article-title":"Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome","volume":"26","author":"Laoag-Fernandez","year":"2000","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0185","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","author":"Luan","year":"2012","journal-title":"Brain Dev."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0190","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"98","author":"Hollak","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","article-title":"Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease","volume":"91","author":"Elstein","year":"1998","journal-title":"Q. J. Med."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0065","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1111\/j.1742-4658.2006.05410.x","article-title":"Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients","volume":"273","author":"Chang","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0070","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12028-011-9642-4","article-title":"High-dose ambroxol reduces pulmonary complications in patients with acute cervical spinal cord injury after surgery","volume":"16","author":"Li","year":"2012","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0080","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/039463200902200407","article-title":"Differential modulation of IgE-dependent activation of human basophils by ambroxol and related secretolytic analogues","volume":"22","author":"Gibbs","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0085","first-page":"256","article-title":"Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo-controlled trials regarding the local anaesthetic properties","volume":"52","author":"Fischer","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0090","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuropharm.2005.08.004","article-title":"Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain","volume":"49","author":"Gaida","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pbb.2010.08.006","article-title":"Antinociceptive effect of ambroxol in rats with neuropathic spinal cord injury pain","volume":"97","author":"Hama","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0301-0546(09)71730-6","article-title":"Ambroxol-induced systemic contact dermatitis confirmed by positive patch test","volume":"37","author":"Monz\u00f3n","year":"2009","journal-title":"Allergol. Immunopathol. (Madr)"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.revmed.2006.05.009","article-title":"Ambroxol-induced immune hemolytic anemia","volume":"27","author":"Guitard","year":"2006","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0151-9638(06)70874-2","article-title":"Ambroxol-induced toxicoderma","volume":"133","author":"Saad","year":"2006","journal-title":"Ann. Dermatol. Venereol."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1442-2042.2007.01474.x","article-title":"Parenteral ambroxol treatment causes xanthine and calcium oxalate stones in rats","volume":"14","author":"Drewa","year":"2007","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0120","first-page":"557","article-title":"Antiinflammatory properties of ambroxol","volume":"13","author":"Beeh","year":"2008","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0125","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0130","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00018-005-5437-0","article-title":"Therapeutic strategies to ameliorate lysosomal storage disorders\u2014a focus on Gaucher disease","volume":"63","author":"Sawkar","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0135","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1039\/c1ob05234a","article-title":"Bicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: effect of structural modifications in their pharmacological chaperone potential towards \u03b2-glucocerebrosidase","volume":"9","author":"Aguilar-Moncayo","year":"2011","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2012.04.018","article-title":"Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant \u03b2-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant","volume":"106","author":"Babajani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0145","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2010.10.012","article-title":"Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant","volume":"46","author":"Bendikov-Bar","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0150","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/17425255.4.8.1119","article-title":"Ambroxol in the 21st century: pharmacological and clinical update","volume":"4","author":"Malerba","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0155","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/bcmd.2002.0497","article-title":"Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease","volume":"28","author":"Heitner","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0160","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0165","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1212\/WNL.43.10.1993","article-title":"Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease","volume":"43","author":"Patterson","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0170","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1528-1167.2007.01074.x","article-title":"Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase\/miglustat combination","volume":"48","author":"Capablo","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcmd.2012.09.006_bb0175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/01.GIM.0000153666.23707.BA","article-title":"Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction","volume":"7","author":"Elstein","year":"2005","journal-title":"Genet. Med."},{"key":"10.1016\/j.bcmd.2012.09.006_bb0180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(89)90536-9","article-title":"Prediction of severity of Gaucher's disease by identification of mutations at DNA level","volume":"2","author":"Zimran","year":"1989","journal-title":"Lancet"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979612001842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979612001842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:28:32Z","timestamp":1761049712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979612001842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1079979612001842"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.09.006","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}